生物试剂
>
生化试剂
>
信号通路
> ANI-7
加入收藏 取消收藏

ANI-7  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：10mg in glass bottle
溶解性：溶于DMSO（20.83 mg/mL 超声）
产品描述：基本信息 产品编号： A11362 产品名称： ANI-7 CAS: 931417-26-4   储存条件 粉末 -20℃ 四年     分子式： C13H8Cl2N2 溶于液体 -80℃ 六个月 分子量 263.12 -20℃ 一个月 化学名：  (Z)-2-(3,4-dichlorophenyl)-3-(1H-pyrrol-2-yl)prop-2-enenitrile Solubility (25°C)：   体外:   DMSO 20mg/mL(76.0109mM;Need ultrasonic) Ethanol   Water   体内(现配现用): 1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline，Solubility:≥2.08mg/mL(7.91mM);Clear solution 此⽅案可获得≥2.08mg/mL(7.91mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL20.8mg/mL的澄清DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。 2.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:≥2.08mg/mL(7.91mM);Clear solution 此⽅案可获得≥2.08mg/mL(7.91mM，饱和度未知)的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以1mL⼯作液为例，取100μL20.8mg/mL的澄清DMSO储备液加到900μL⽟⽶油中，混合均匀。 ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 3.8005mL 19.0027mL 38.0055mL 5mM 0.7601mL 3.8005mL 7.6011mL 10mM 0.3801mL 1.9003mL 3.8005mL   生物活性 产品描述 一种AhR途径的激活剂。ANI-7抑制多种癌细胞的生长，并有选择地抑制MCF-7乳腺癌细胞的生长，GI50为0.56μM。ANI-7通过激活AhR途径诱导CYP1代谢单加氧酶，并在敏感的乳腺癌细胞系中诱导DNA损伤，检查点激酶(Chk2)激活，S期细胞周期停滞和细胞死亡。 靶点 Aryl Hydrocarbon Receptor Chk2 体外研究 ANI-7 (2.5μM; 24 hours; MCF10A and MDA-MB-468 cells) treatment induces significant S-phase and G2 + M-phase cell cycle arrest within 24 hours of treatment in MDA-MB-468 cells, and negligible effect in normal breast MCF10A cells[1] . ANI-7 (2μM; 12-24 hours; MDA-MB-468 cells) treatment results in a significant increase in the content and phosphorylation of CHK2, and induces a significant increase in H2AXɣ in MDA-MB-468 cells, indicative of DNA double-strand damage[1] . Inhibition of the AhR pathway ameliorates the effects of ANI-7. ANI-7 activates XRE activity and expression of the AhR and CYP1 members Comparisons of the GI50 values show that ANI-7 produces a GI50 value of 0.38μM in MCF-7 cells, whereas values of 3.0-42μM are observed in cell lines from lung, colon, ovary, neuronal, glial, prostate, and pancreas. The only other tumor type that shows appreciable growth inhibition by ANI-7 is the A431 vulva cell line (GI50 of 0.51μM)ANI-7 potently inhibits the growth of T47D, ZR-75-1, MCF-7, SKBR3, and MDA-MB-468 breast cancer cells (GI50 range of 0.16- 0.38μM), moderately inhibits the growth of BT20 and BT474 cells (GI50 range of 1-2μM), and essentially fails to inhibit the growth of MDA-MB-231 and MCF10A cells (GI50 range of 17-26μM). Moreover, ANI-7 maintained its ability to inhibit the growth of drug-resistant cells (MCF-7/VP16: GI50 of 0.21μM) Cell Cycle Analysis[1 Cell Line: MCF10A and MDA-MB-468 cells Concentration: 2.5μM Incubation Time: 24 hours Result: Induced significant S-phase and G2 + M-phase cell cycle arrest in MDA-MB-468 cells, and negligible effect in normal breast MCF10A cells. Western Blot Analysis Cell Line: MDA-MB-468 cells Concentration: 2μM Incubation Time: 12 hours, 24 hours Result: Resulted in a significant increase in the content and phosphorylation of CHK2 (25-fold increase),and induced a significant increase in H2AXɣ (3.5-fold increase).
保存条件：-20℃

猜你喜欢